Hemogenyx Pharmaceuticals annual stock-based compensation
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Stock-Based Compensation Growth & History (HEMO)
Hemogenyx Pharmaceuticals's stock-based compensation was £63,152 for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £63,152 | −£280,783 | −81.64% |
| 2024 | 2024-12-31 | £343,935 | £101,099 | +41.63% |
| 2023 | 2023-12-31 | £242,836 | £225,261 | +1281.71% |
| 2022 | 2022-12-31 | £17,575 | −£135,780 | −88.54% |
| 2021 | 2021-12-31 | £153,355 | −£209,749 | −57.77% |
| 2020 | 2020-12-31 | £363,104 | — | — |
Hemogenyx Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Hemogenyx Pharmaceuticals's stock-based compensation decreased from £363,104 to £63,152, a change of −£299,952.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
reported stock-based compensation
TickerStat standardizes share-based compensation reported in company official filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗